Precision Nanomedicine Targeting Only Diseased Tissues

Ashvattha Therapeutics is leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class of precision medicines that selectively treat diseased cells only in regions of inflammation. By making precision medicine even more precise, our nanomedicine technology has the potential to change the standard of care across ophthalmology, neurology, inflammatory diseases and neuro-oncology.​

Welcome to Ashvattha

Ashvattha Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel nanomedicines enabled by our hydroxyl dendrimer (HD) technology to treat unmet medical needs in ophthalmology, neurology, inflammatory diseases and neuro-oncology. Our HD platform builds therapeutics that are selectively taken up only by inflamed tissues, allowing us to treat diseases with unprecedented precision.

Jeffrey Cleland, Ph.D., Ashvattha Chairman, CEO and President interview with Health Professional Radio, July 1, 2021

"Potential COVID Treatments That Address Brain Inflammation"

We have designed and optimized a nanomedicine that precisely targets reactive macrophages. microglia and retinal pigment epithelial cells (RPEs) after systemic administration

Our solution enables patient selection followed by treatment with anti-neuroinflammatory nanomedicine to target reactive microglia

OP-101 selectively targets pro-inflammatory macrophages and microglia responsible for excessive cytokine production

We are developing nanomedicines leveraging our ability to target tumor associated macrophages (TAMs)

Pipeline: Value-Creating Outcomes

Latest News